Search
Remimazolam
go.drugbank.com/drugs/DB12404ApprovedInvestigationalRemimazolam is an ultra short-acting benzodiazepine used in the induction and maintenance of sedation during short (<30 minute) procedures. … [L14647] Recent trends in anesthesia-related drug development have touted the benefits of so-called "soft drugs" - these agents, such as [remifentanil], are designed to be metabolically fragile and thus
VIT-100
go.drugbank.com/drugs/DB05865ExperimentalVIT-100 was developed by ItherX Pharmaceuticals of San Diego.
Galiximab
go.drugbank.com/drugs/DB04901InvestigationalGaliximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug.
CYT-6091
go.drugbank.com/drugs/DB05991ExperimentalCYT-6091 (Aurimune) is an investigational small molecule made up of recombinant human tumor necrosis factor alpha (rhTNF) and thiolyated polyethylene glycol bound to the surface of 27 nm colloidal gold
Pertuzumab
go.drugbank.com/drugs/DB06366ApprovedInvestigationalIts indicated conditions have since expanded to include use as both a neoadjuvant therapy and an adjuvant therapy in the treatment of HER2-positive breast cancers at high risk of recurrence.
Olaparib
go.drugbank.com/drugs/DB09074ApprovedInvestigational[L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014,[A246020] and by Health Canada in April 2016.[L42820]
Categories: Cytochrome P-450 CYP2B6 Inducers, P-glycoprotein inhibitorsFerrous asparto glycinate
go.drugbank.com/drugs/DB11169ApprovedFerrous asparto glycinate is an iron-amino acid chelate. It is available as a dietary supplement used in the treatment of iron deficiency and iron deficiency anemia.
Urethane
go.drugbank.com/drugs/DB04827ApprovedWithdrawnUrethane, formerly marketed as an inactive ingredient in Profenil injection, was determined to be carcinogenic and was removed from the Canadian, US, and UK markets in 1963.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2E1 Substrates